For US Trastuzumab Biosimilars, Development Time Did Not Predict Speed To Market

 
• By Sue Sutter

Amgen/Allergan's Kanjinti had second longest development time among five licensed biosimilars to Genentech's Herceptin but was the first to reach market, according to a Pink Sheet timeline of development and regulatory milestones for the follow-on products.

Race driver pass the finishing point and motion blur backgroud. 3D rendering - Illustration
Speed to approval does not always equate to speed to market. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics